Adenovirus type 4 and type 7
Ended Awarded
- Contract number
- SPE2DP26F7449
- Awardee
-
Teva Pharmaceuticals Usa, Inc. UEI NEN9A34LRHJ5
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $515,290
Award facts
- Contract value 100% obligated
- $515,289.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Parsippany, NJ 07054, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency Medical Supply Chain issued a delivery order to Teva Pharmaceuticals USA, Inc. on July 14, 2026, with a ceiling value of $515,289.60 for Adenovirus Type 4 and Type 7 vaccine, completing by July 21, 2026.
Place of performance is Parsippany, New Jersey. The order is firm fixed price with no set-aside applied.
Quick answers
Who was awarded contract SPE2DP26F7449?
SPE2DP26F7449 was awarded to Teva Pharmaceuticals Usa, Inc. by Medical Supply Chain (Troop Support) on July 14, 2026.
How much is contract SPE2DP26F7449 worth?
The government has obligated $515,290 on SPE2DP26F7449.
Is contract SPE2DP26F7449 an order under another contract?
Yes. SPE2DP26F7449 is a delivery order under SPE2DP20D0002, an indefinite delivery contract.
Was contract SPE2DP26F7449 competed?
The extent of competition for SPE2DP26F7449 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award